CA-ULTRAVIOLET-DEVICES
14.1.2021 14:47:33 CET | Business Wire | Press release
UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10 , inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters). Testing on the coronavirus strain that causes the COVID-19 disease was conducted by Innovative Bioanalysis, a CAP, CLIA, and BEI-recognized BSL-3 certified laboratory (CA, USA). The Centers for Disease Control and Prevention (CDC) has indicated that the COVID-19 disease can be spread by both surface and airborne transmission of SARS-CoV-2.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005585/en/
The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals. The UVDI-360 Room Sanitizer has previously been proven to help prevent Healthcare-Associated Infections and to inactivate over 35 pathogens, including human coronavirus (229E), in over 10 peer-reviewed published clinical studies and independent laboratory testing.
“We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.” stated Peter Veloz, Chief Executive Officer, UVDI. “Specific to use in hospitals for whole room disinfection, we believe that proving rapid inactivation of pathogens at distances of 8 feet (2.44 meters) and 12 feet (3.65 meters) is the best marker for in-facility performance. Independent confirmation of effectiveness against high-risk pathogens is a common sense, yet critical step to verify disinfecting claims for UV devices.”
“Building on our deep science-based evidence demonstrating the UVDI-360’s effectiveness against high-risk pathogens, including coronaviruses, we feel the healthcare professionals we serve globally deserve proof against the specific SARS-CoV-2 viral strain causing COVID-19,” added Dr. Ashish Mathur, Vice President of Innovation and Technology, UVDI.
About UltraViolet Devices, Inc.
UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California, applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate high-risk pathogens. UVDI’s proven Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).
1 https://www.cdc.gov/coronavirus
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005585/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
